GLP-1 Drug Patent Expiration Tracker: U.S. Patents & Generic Status

Updated: September 25, 2026 · FDA Paragraph IV snapshot: September 14, 2026 · Dataset version 2.0 · Prior research review: August 19, 2026

Source dates differ. FDA filing records, approval records, litigation checks, and price observations have their own dates; updating this page does not make every historical observation current. This editorial refresh does not create a new dataset release or certify a fresh product-level Orange Book patent register.

Disclosure: This research page contains no affiliate links and no paid rankings. Nobody pays to appear here. This is patent and regulatory research, not medical or legal advice.

There is no single U.S. GLP-1 patent expiration date. This GLP-1 drug patent expiration tracker separates the five things that get mashed into one headline: listed patents, FDA exclusivity, Paragraph IV filings, FDA approval, and actual pharmacy availability. FDA-approved generics reference three older brands—Byetta, Victoza, and Saxenda—covering two active ingredients, exenatide and liraglutide. Semaglutide and tirzepatide have Paragraph IV filings, with qualifying-patent dates shown into the 2040s; those dates are not launch forecasts.

Here's the part almost nobody tells you: Apotex says a proposed generic version of Ozempic has already received tentative FDA approval in the United States. It still isn't for sale, and the reason why is the whole story on this page.

Best for / Not for you

This page is for you when you need to:

• Look up patent and generic-entry milestones for a specific GLP-1 brand and form
• Understand why 2026, 2032, 2033, 2039, and 2041 all show up in articles about the same drug
• Tell the difference between "FDA approved it" and "you can buy it"
• Check a headline you just read against the actual government record

This page is not for you when you need:

• An exact day a generic will hit your pharmacy — nobody can give you that, including us
• A ruling on whether a patent is valid or being infringed
• Advice about your own prescription — that's a conversation with your clinician
• Availability outside the U.S. — see our generic semaglutide availability by country tracker
• Permission to treat a compounded drug as a generic — it isn't one, and we explain why below

What we actually verified

We checked:

• The FDA Orange Book patent and exclusivity records in the earlier research review; this update does not re-certify every patent and product-number association
• FDA's September 14, 2026 Paragraph IV PDF and its strength-specific row data, retrieved and checked September 25, 2026
• FDA's first-generic approval tables for exenatide and liraglutide products
• Separate company launch or product records for the older approved generics
• Novo Nordisk's Q2 2026 financial report, including its adjusted-sales table and reconciliation
• Health Canada's previously cited dated approval announcements and its September 16, 2026 Sandoz product-status record checked for this update
• The August 2026 litigation observations and company announcements cited below; the current docket status was not independently rechecked in this refresh

We did not claim:

• An exact future generic launch date for any product
• That every approved generic is currently on a pharmacy shelf
• That any listed patent is valid, infringed, or legally blocking a specific company
• That a compounded medication is a generic
• That a foreign patent date applies in the United States

Company-stated vs. independently verified

That middle row matters. The tracker says “Apotex announced tentative approval” rather than turning a company release into an unqualified FDA claim. That is not a wording trick. It is the line between what the company says and what we independently attached to the record.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

GLP-1 drug patent expiration tracker: status at a glance

Notice what that column is doing. It shows evidence status, not a launch year. A year like "2033" tells you almost nothing on its own. A Paragraph IV filing and an FDA approval are different events; older company launch records do not confirm current pharmacy stock.

One thing this tracker cannot do

We cannot tell you the exact day a generic GLP-1 will reach your pharmacy. Nobody can. Patent lawsuits, private settlements, FDA review times, factory capacity, and a company's own launch decision can all move that date — in either direction.

The FDA says the same thing about its own data. Its position is that patent and exclusivity dates give a rough estimate at best, and that generics are sometimes approved before every listed patent and exclusivity has expired.

We think that admission makes this tracker more useful, not less. Every page that hands you one confident year is quietly hiding four moving parts. We separate their source dates and identify what was not newly checked. A countdown clock means this is the wrong site. The evidence and its limits are below.

Why is there no single GLP-1 patent expiration date?

A drug does not automatically go generic when one patent expires. Generic entry depends on four moving parts — patents, FDA exclusivity, litigation or settlement, and manufacturing and launch. The part that still blocks approval or sale is the one that matters most. This is why articles about the same drug print different years and several of them can be technically accurate.

Here are the four moving parts in plain English.

A patent is private property — the drugmaker's ownership of an invention. FDA exclusivity is something else entirely: a period where the government limits when a copy can be submitted or approved, regardless of who owns what. They are two different systems, and they routinely end on different dates.

Most people have never heard of clock #2. It can be the one that matters most.

We'll show you the clearest proof further down, in Canada, where the key active-ingredient patent was already listed as expired but separate data protection still ran until January 4, 2026.

The right treatment path isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path (injection or oral), and your budget. Because a patent date can't resolve any of that for you, use The RX Index's Find My GLP-1 Path tool to see which treatment paths are actually open to you today, with source-verified pricing.

Which GLP-1 drugs already have FDA-approved generics?

Generics have FDA approvals referencing Byetta, Victoza, and Saxenda. These are three reference brands, not three distinct active ingredients. The first generic referencing Byetta was approved November 19, 2024, Victoza December 23, 2024, and Saxenda August 27, 2025. They cover exenatide and liraglutide, not semaglutide or tirzepatide.

Most people are surprised by this. The GLP-1 generic era already started in the U.S. It just started with the drugs almost nobody is asking about.

These dates come from the FDA's own 2024 and 2025 first-generic approval tables. They are not estimates.

For the separate market check, Hikma announced the U.S. launch of its generic referencing Victoza in December 2024, Teva announced the launch of its generic referencing Saxenda in August 2025, and Amneal lists an approved exenatide injection in its portfolio. Company announcements and listings are not independent confirmation of current nationwide pharmacy stock. An authorized generic may also be marketed under the brand product's approved NDA rather than a separate ANDA.

Two things to be careful about here.

First, Victoza and Saxenda are not interchangeable. They both contain liraglutide, but they are separate FDA products with separate approvals. A generic referencing Victoza is approved for diabetes. A generic referencing Saxenda is approved for weight management. Same molecule, different rulebook rows.

Second — and this is the rule the whole page runs on — FDA approval does not prove the drug is at your pharmacy. The FDA states this itself in the same tables where it publishes these dates: an approved drug may not be available on or immediately after its approval date. Approval means FDA cleared the product for marketing. Someone still has to make it, ship it, and stock it.

So we track those as two separate fields. Approval date is one column. Verified retail availability is another. We will never merge them.

What did going generic actually do to the price?

Less than most people expect, at first. Optum Rx reports that the average list price of a first generic is often only 10–15% below the brand. Its cited U.S. review found declines of about 15–40% with 3–5 competitors and 60–90% with 10 or more. Health Canada says many generics there cost 45–90% less than the brand. The discount depends on competition, not on the day one patent expired.

This is the most important section on this page, because it answers the question underneath the question. Nobody types "patent expiration tracker" because they enjoy patent law. They type it because they want to know when this stops costing so much.

Here is the honest answer, built from what has already happened rather than what anyone predicts.

The official numbers that look like a contradiction

All three can be true. They're measuring different markets and different stages of competition. The first entrant usually starts the price fight. A crowded market is what drives the deeper cut.

That means the date you're waiting for isn't the finish line. It's the starting gun. The real savings deepen only when enough companies actually make and sell competing products.

What happened to the GLP-1s that already went generic

The following figures come from Novo Nordisk's Q2 2026 financial report, including its adjusted-sales table and reconciliation. These are company-reported financial measures. They describe manufacturer revenue, not a patient's prescription price, and do not isolate the effect of generic competition.

These are global product-sales measures, not a U.S.-only retail-price series. Novo's Canada statement describes its own realized prices and volumes; it is not a measured patient discount.

Historical price example: generic liraglutide on August 19, 2026

This is the part that will save some readers a year of false hope. A generic GLP-1 has been on the U.S. market since 2024. It is still not automatically cheap.

These are historical advertised cash or discount-price observations, not current quotes or guaranteed insurance copays. Product, quantity, pharmacy, location, coupon conditions, and stock can change the price. In the displayed five-pen Saxenda comparison, the recorded generic price was approximately 72% below the recorded brand price. That example does not predict the price of a future semaglutide or tirzepatide generic.

A U.S. launch date and price for a future generic semaglutide have not been established by the evidence cited here. Do not base a treatment budget on an unconfirmed launch or price projection. For current costs, see the GLP-1 price and access tracker.

What actually changes your cost in the next 12 months isn't a patent date. It's your plan's formulary, manufacturer self-pay pricing, and whether you qualify for the Medicare GLP-1 Bridge. We track all three, with dates, in our GLP-1 price and access tracker.

When could generic Ozempic, Wegovy, or Rybelsus arrive?

No U.S. launch date is established for any semaglutide product in the evidence here. FDA's Paragraph IV PDF is dated September 14, 2026; its listed rows show challenges against the semaglutide reference products below. Apotex has announced tentative FDA approval for a proposed generic Ozempic injection. Tentative approval is a milestone, but it is not final approval and does not authorize U.S. marketing.

Let's go product by product, using the FDA's own Paragraph IV Certifications List.

A Paragraph IV certification is a formal statement filed by a generic company saying, in effect: we believe your patent is invalid, unenforceable, or that our product wouldn't infringe it, so approve us anyway. It's the legal starting pistol for a generic challenge.

Semaglutide: the current Paragraph IV record

How to read the patent-date column: FDA's “Expiration Date of Last Qualifying Patent” is a field used in administering 180-day generic exclusivity. It is not a complete Orange Book patent list, is not necessarily the latest patent listed for a product, and does not include associated pediatric exclusivity. Do not treat it as the date all protection ends or a generic launch forecast.

Source: FDA Paragraph IV Certifications List, PDF dated September 14, 2026; retrieved and checked September 25, 2026. Counts are applications in each FDA row, not a deduplicated company count. The PDF SHA-256 is 8ec4d45eea25faf6ba3deb12114a39526817aeeba170ccad4564feaafb2e5964.

Now look at what those rows show when you place them together.

The selected Ozempic and Wegovy Paragraph IV rows show dates 2,798 days apart. That compares one defined FDA field across different reference-product rows. It does not measure the difference between the brands' complete patent estates or establish a 7-year-and-8-month gap between generic launches.

And the largest Ozempic row shows seven potential first-applicant ANDAs. Standard Wegovy shows one. We can't tell you why from the public record, but that's a striking split worth watching. We also cannot turn those row counts into a reliable count of unique companies.

A date pattern we computed from the FDA record

Look at Ozempic's first Paragraph IV date: December 6, 2021.

Ozempic was approved December 5, 2017. Under U.S. law, a new chemical entity gets five years of exclusivity, but a generic company may file a Paragraph IV challenge after four years — a point the industry calls NCE-1. Four years after December 5, 2017 was December 5, 2021.

December 5, 2021 was a Sunday.

The first challenge is dated Monday, December 6, 2021 — one day after the four-year date and the first business day after it.

That timing strongly suggests generic applicants were ready to file as soon as the window opened. Hold that thought, because the tirzepatide section below shows the same pattern in an even more dramatic form.

What the Apotex announcement means

Apotex announced on April 10, 2026 that its semaglutide injection application had received tentative FDA approval — which it described as the first for a generic version of Ozempic in the United States.

That is genuinely significant. It means the application moved beyond filing and reached a tentative approval decision.

Tentative approval does not authorize U.S. marketing and does not establish a final-approval or commercial-launch date.

Tentative approval means final approval is delayed because a patent or exclusivity still blocks it. The product cannot be marketed under that tentative approval. You cannot fill it.

We are publishing this as Apotex announced rather than as a flat FDA fact because the proof attached here is the company's April 10 release, not a linked FDA approval letter. The FDA Paragraph IV record independently confirms that an Ozempic challenge exists. It does not, by itself, prove tentative approval.

One more filing worth watching

Novo Nordisk's August 4, 2026 securities filing discloses that Cipla notified Novo Nordisk that it filed a U.S. application for a generic Ozempic with Paragraph IV certifications, and Novo sued Cipla for patent infringement in federal court in New Jersey.

The same filing says that on June 30, 2026, Sandoz sued Novo Nordisk in the Unified Patent Court in Milan, asking the court to cancel a European patent covering the 1 mg semaglutide dose for diabetes across 18 EU countries.

Neither event means a cheaper U.S. drug is coming soon. Both mean the fight has actually started.

When could generic Mounjaro or Zepbound arrive?

No U.S. launch date is established for either in these records. FDA records show first Paragraph IV filings against both Mounjaro and Zepbound dated May 13, 2026 — the four-year filing point. The earlier August research review reported 14 Lilly patent complaints against generic challengers on August 6, 85 days later; this update does not recheck the current docket status.

This is the clearest example on the whole page of the gap between "you may file" and "you may sell."

Tirzepatide: the current Paragraph IV record

The last qualifying patent expiration here is the FDA Paragraph IV field defined above, not a complete patent register or predicted generic launch date. Rows retain the source's strength and presentation groups; “subcutaneous solution” alone does not identify a device.

Source: FDA Paragraph IV Certifications List, September 14, 2026 PDF; retrieved and checked September 25, 2026. Strength groups and counts are copied individually; they are not a count of distinct manufacturers.

The May 13 finding

Mounjaro was approved May 13, 2022. Four years later — the NCE-1 point for tirzepatide — was May 13, 2026. A Wednesday. A business day.

The first filings are dated May 13, 2026. Not a day later. Zero days after the four-year point.

With semaglutide, the first recorded challenge came on the first business day after the four-year date. With tirzepatide, the filings came on the literal date. And the FDA did not show one potential first applicant — it showed 13 potential first-applicant ANDAs on the largest Mounjaro rows and 12 on Zepbound's.

Lilly told investors in its August 5 quarterly filing that it had received Paragraph IV notices during July. In the prior research review, August 6, 2026 docket records were cited for 14 complaints in Delaware federal court. The cited Sandoz case record listed a November 13, 2029 stay-related deadline; it is case-specific and subject to later legal developments, not a generic tirzepatide launch date. This September article update does not independently establish the current docket status or whether that date was a court-entered deadline.

That sequence — first recorded filing date → multiple potential first-applicant ANDAs per row → litigation reported 85 days later — shows active generic-development and patent-challenge activity. It does not establish manufacturing or launch readiness.

Do not add these numbers together

This matters and almost every write-up gets it wrong.

Those counts are per FDA row, not per company. The same manufacturer can appear on the 2.5 mg row, the 7.5 mg row, and the 15 mg row. Adding 13 + 13 + 12 does not give you 38 companies. It gives you a meaningless number.

We show each source-defined strength/presentation group separately in the table above. Dataset 2.0 does not include a downloadable row-level Paragraph IV file; a future release would need a separately verified export. We will not publish a summed manufacturer total because the FDA field does not support one.

A realistic read for a patient: The earlier research review reported a May 13, 2036 tirzepatide compound-patent date, but this editorial update has not independently revalidated its patent and product identifier against the current Orange Book file. It is not a guaranteed launch date. Even if a challenger wins or settles earlier, FDA status, manufacturing, and launch still have to line up.

If that's you, don't guess your way through it. See which GLP-1 treatment paths are open to you right now → The tool checks your state, your coverage, and whether you want an FDA-approved or compounded medication, then shows you what it actually costs. It takes about two minutes, and no purchase is required to use it.

Why does Canada already have generic Ozempic?

Because Canada's clocks ended earlier — and not in the order most people assume. Novo Nordisk's key Canadian active-ingredient patent was already listed as expired, while Health Canada's separate data-protection register ran until January 4, 2026. Health Canada approved the first generic semaglutide on April 28, 2026, becoming the first G7 country to do so.

This is the single best proof that a patent is not the only thing standing between you and a cheaper drug.

Selected Canadian milestones (not a complete census of approved products):

That 13-day approval-to-launch interval is a useful real-world number. It shows that a product can move fast once the legal, regulatory, and manufacturing pieces are all ready. It does not tell us how fast any U.S. product will move.

Those figures describe Health Canada's announcements on April 28, May 1, and June 29, 2026. They are historical snapshots, not today's queue total; additional applications can enter the queue. See our generic semaglutide availability by country tracker for country-specific updates.

Can I buy the Canadian generic from the U.S.?

Don't plan on it.

The FDA says that, in most circumstances, it is illegal for an individual to import a prescription drug that is not approved in the United States. FDA has narrow enforcement-discretion policies and separate government importation pathways, but neither turns a Canadian online order into routine U.S. pharmacy access. A product approved by Health Canada is not an FDA-approved product for U.S. purposes.

For the full country-by-country picture — India, Brazil, China, Canada, and other markets — use our generic semaglutide availability by country tracker.

What do the dates in this tracker actually mean?

Each date answers a different question. A patent date describes one listed patent. Exclusivity describes an FDA approval restriction. A Paragraph IV date marks a legal challenge. Tentative approval, final approval, first commercial marketing, and verified pharmacy availability are four more separate events.

Seven milestones can appear in a record. Not every product hits all seven, and they do not always happen in this exact order. The point is that none of them means the same thing.

1. Listed patent expiration. The date the brand company submitted to the FDA for a patent it listed, including any extension shown in the record. It is not a generic launch date. The FDA publishes what the company submits; the listing is not an FDA ruling that the patent is valid or infringed.

2. FDA exclusivity. A separate government block that can limit submission or approval of a copy. It runs on its own schedule. It can outlast a patent or end first.

3. Paragraph IV certification filed. A generic company has formally challenged at least one listed patent. This is a filing, not a win.

4. Tentative approval. The FDA has made a tentative approval decision, but a patent or exclusivity still blocks final approval. The product cannot be marketed under tentative approval.

5. Final approval. The FDA has cleared it for marketing. That still doesn't prove it is in stock anywhere.

6. First commercial marketing. The company actually started selling it. This can happen after approval, and the interval varies.

7. Independently verified retail availability. This would require a dated pharmacy or distributor check that the product can actually be filled. It is not an FDA status and has not been newly established for the products on this page.

When you read "the patent expires in 2033," you are looking at only one of up to seven milestones.

Can a generic be approved before the last patent expires?

Yes. It happens. A Paragraph IV certification lets a generic company seek approval before listed patents expire by arguing they're invalid, unenforceable, or not infringed. Litigation, settlements, and the specific scope of each patent can all change the sequence, which is exactly why the latest date in a patent table cannot be treated as an automatic launch date.

Here's how the machinery usually works, in three steps.

Step 1 — the filing. A generic company submits its application with a Paragraph IV certification saying at least one listed patent is invalid, unenforceable, or wouldn't be infringed by its version.

Step 2 — the notice. The brand company and patent holder get formal notice. They generally have 45 days after receiving it to sue.

Step 3 — the stay. If they sue in time, final FDA approval is generally postponed for 30 months from receipt of the notice while the case plays out — unless a court decision or another listed event shortens, extends, or ends the stay. There is a special NCE-1 rule: when the application is submitted between years four and five of new-chemical-entity exclusivity and suit is filed during that period, the stay can be extended so 7.5 years have elapsed from the brand's approval date.

That is why the August 6, 2026 Lilly cases matter. They are not just legal paperwork. A timely suit can delay final approval, and each challenger can have a different notice date and stay deadline.

There's also a 180-day first-applicant reward. The first substantially complete applicant or applicants with a qualifying Paragraph IV certification may earn 180-day exclusivity that can delay approval of some later ANDAs. Multiple first applicants can share it, and an authorized generic is treated differently. It is not safe to translate the rule into “one company will be the only generic seller for exactly 180 days.”

Why some fields in our tables are blank

For records after 2019, a blank approval or marketing field in the FDA's Paragraph IV data means the event has not happened or the determination has not been made. It does not mean a secret approval. It does not mean permanently blocked.

We leave blanks blank. A blank alone does not prove that no event occurred or that the latest approval-status check is complete.

Why does the same GLP-1 show five different expiration years?

Because one drug can appear across several brands, FDA applications, product numbers, strengths, forms, indications, and patent categories — each with its own date. A single brand-level year hides all of that. The Paragraph IV tables on this page identify applications and strength groups; they are not a complete product-number-level patent register.

Walk down the ladder and you'll see where the confusion comes from:

• A drug is not a brand. Semaglutide is Ozempic and Wegovy and Rybelsus.
• A brand is not an application. Injectable and oral versions can sit under different FDA applications.
• An application is not a product. The FDA assigns separate product numbers and strength groups to different doses, containers, and devices. Mounjaro's autoinjector and KwikPen appear in separate rows.
• A patent is not one kind of thing. A drug-substance patent covers the molecule. A drug-product patent can cover the formula or device. A use patent covers a specific approved use. A use patent can run years past a molecule patent and cover a narrower slice.
• Some patents are being removed. When a company requests that a patent be delisted, it can still appear in FDA data for legal reasons. A future patent register must preserve that source flag; the Paragraph IV tables above do not display individual patents.
• Pediatric exclusivity can add six months. It attaches to an existing patent or exclusivity rather than standing alone, which is why some records show a base date and a later protected date.

The 10-question test for any patent headline

Next time you see "Ozempic patent expires in [year]," run this:

1. Which country?
2. Which brand?
3. Which FDA application number?
4. Which product or strength?
5. Which patent category — substance, product, device, or use?
6. Does the date include an extension or pediatric exclusivity?
7. Is there a Paragraph IV filing?
8. Is there a tentative approval?
9. Is there a final approval?
10. Has anyone confirmed it's actually in pharmacies?

An article that cannot answer those questions has not earned a confident launch year.

Trulicity uses the biosimilar pathway, not the ANDA generic pathway

Trulicity (dulaglutide) is a biologic, not a conventional drug. It was approved under Biologics License Application 125469 and appears in the FDA's Purple Book rather than the Orange Book, so follow-on versions would be biosimilars — not generics. Its original FDA approval date was September 18, 2014.

This trips up a lot of otherwise good articles, and it works in the other direction too — several pages claim semaglutide and tirzepatide need biosimilars. They don't. FDA treats semaglutide, tirzepatide, liraglutide, exenatide, and orforglipron as drugs under NDAs, and the Paragraph IV records show the generic pathway in use.

So when someone asks "when does Trulicity go generic," the technically correct answer is: it doesn't. It may eventually have biosimilars, which is a different pathway with different rules.

September 18, 2026 was the 12-year anniversary of Trulicity's original FDA approval on September 18, 2014. That calculated anniversary is not itself a biosimilar approval, a commercial launch, or a finding that every patent barrier has ended.

In the Purple Book records cited in the prior August 19 review, Trulicity was listed under BLA 125469 and no FDA-licensed dulaglutide biosimilar was identified. The individual Purple Book product status and exclusivity field were not newly rechecked for this editorial update. Reference-product exclusivity, patents, biosimilar licensure, and actual launch must still be tracked separately.

Is compounded semaglutide or tirzepatide a generic?

No. FDA-approved generics and compounded drugs are two different categories under U.S. law. A generic goes through an FDA application process and must meet FDA requirements before approval. A compounded drug is not FDA-approved as a finished product — the FDA does not review it for safety, effectiveness, or quality before it's sold.

We're including this section because it's the most common way people get misled on this exact topic, and because we will not let a compounded product appear anywhere in this tracker's generic-status columns.

How to recognize a real FDA-approved generic. You should be able to find all of these:

• An FDA application number
• An FDA approval record you can look up
• A named applicant company
• The reference brand it copies
• The approved strength and form

If the product identity and approval details cannot be verified, treat the generic claim as unverified. A pharmacist can help check the product against FDA records. An authorized generic may be marketed under the original brand NDA, rather than a separate ANDA.

Phrases that should make you pause:

• "Generic Ozempic" with no FDA record behind it
• "Same as Ozempic"
• "FDA-approved pharmacy" used in a way that implies the medication itself is FDA-approved
• A telehealth brand name presented as if it were the drug manufacturer

None of this means compounded medication is illegitimate or that people using it are making a mistake. Compounding is a real, regulated practice with real clinical uses. It is simply not the same category as an approved generic, and any page that blurs the two is doing you a disservice.

Our own count is simple: zero compounded products appear in any generic-approval row in this tracker. That is a decision rule, not a judgment about an individual prescription.

For the full explanation of how these categories differ, use our guide to GLP-1 biosimilars vs. generics.

What changed recently

This is the part a static patent table can't give you. Newest first.

What happens next

Dated, with what each date does and does not prove.

One note on that January 2027 row, because readers mix these up constantly: a price cut is not a patent event. Novo chose to lower its list price. No patent expired to make that happen. It's on this calendar precisely because it may move your cost sooner than any patent on this page.

What can I do if I can't wait for a generic?

Don't start, stop, or switch a prescription because of a projected patent date. The compound-patent dates reported in the earlier research review are not guaranteed generic launch dates and their individual patent/product associations were not reverified in this update. What can move your cost sooner is your plan's formulary, manufacturer self-pay pricing, appeals, and program eligibility.

Here's the honest framing. For the overwhelming majority of people reading this page, waiting is not a plan. A future patent date is no substitute for checking coverage and available prices now.

That doesn't mean you're stuck. It means the lever you're reaching for is the wrong one.

Things that can change your cost this year:

• Your plan's formulary and prior-authorization rules, which can change at renewal and sometimes mid-year
• Manufacturer self-pay pricing, which has moved several times in the last 18 months
• Medicare GLP-1 Bridge eligibility, for eligible Part D beneficiaries seeking Foundayo, Wegovy injection or tablets, or Zepbound KwikPen for weight management, subject to prior authorization
• An appeal after a denial — check the written denial for the reason, deadline, and appeal route
• A clinician-reviewed decision between FDA-approved and compounded treatment paths, which has real trade-offs in both directions and should never be treated as a simple price swap

A future patent date does not determine what you will pay this year. Current coverage and pricing options need a separate check.

Decide whether waiting is realistic for you

Run this quick check:

• Do I need treatment now, or can it genuinely wait years?
• Is the milestone I'm counting on only a patent date, or is there an actual approval?
• Has anyone confirmed a product is being sold, not just approved?
• Is my drug's date inside five years, or beyond it?

If you answered "I need something now" to the first one, the patent calendar isn't your answer.

Find out which GLP-1 treatment paths are open to you today →

The RX Index's Find My GLP-1 Path tool checks your state, your insurance situation, whether you want an FDA-approved or compounded medication, your preferred treatment path, and your budget — then shows what's actually available to you with source-verified pricing. It's free, takes about two minutes, and The RX Index's consumer health data policy says it does not sell consumer health data.

How we built and verified this tracker

This article distinguishes FDA product/patent and exclusivity records, Paragraph IV strength groups, approvals, company launch announcements, and independently checked retail stock. The September 14 Paragraph IV rows were checked against the FDA PDF on September 25; individual Orange Book patent/product associations, current litigation outcomes, and current retail prices were not all newly verified. The page is not a complete downloadable patent register, and dataset version 2.0 is unchanged.

Our source order

1. FDA Orange Book product, patent, and exclusivity files
2. FDA Paragraph IV Certifications List, using the downloaded PDF's September 14 release label and checking the strength-group rows themselves
3. Drugs@FDA approval records and approval letters
4. FDA first-generic approval reports
5. USPTO records for patent-term details
6. Court records for anything about litigation
7. Company securities filings and press releases for company-specific announcements
8. Pharmacy, manufacturer, and wholesaler checks for actual availability
9. Reputable secondary sources for context only — never as the deciding authority when a primary record exists

Rules we don't break

On joining data: in a future row-level patent dataset, join Orange Book product, patent, and exclusivity records on application type, number, and product number. Paragraph IV groups may span multiple products, so do not assign a single product number by inference. Keep strength and presentation groups separate. Never merge oral and injectable products or diabetes and weight-management reference products without labeling the difference.

On patents: a future row-level register must retain individual patent and product identifiers, date and flags from the Orange Book; it must not infer a device classification from the drug-product flag alone or call the latest listed date "the generic date." Never publish an opinion on whether a patent is valid or infringed.

On Paragraph IV rows: keep each strength and presentation group separate. Preserve the FDA's row-level counts. Never infer a unique company count from an ANDA count. Never add overlapping counts together. Leave blank fields blank rather than treating them as proof of no event. FDA's PDF is dated September 14, 2026; the downloaded PDF was checked September 25 (SHA-256 8ec4d45eea25faf6ba3deb12114a39526817aeeba170ccad4564feaafb2e5964). FDA's last-qualifying-patent expiration is an exclusivity-administration field, not a complete patent expiration or generic launch date.

On approvals: tentative approval is not final approval. Final approval is not commercial marketing. Commercial marketing is not nationwide pharmacy stock. Each gets its own field.

One thing we did that we haven't seen in a normal brand-level tracker

We ran the semaglutide and tirzepatide filing dates shown on this page against the four-year NCE-1 point. The two first-day patterns hold: Ozempic's record lands the first business day after the date, and the first Mounjaro and Zepbound records land on the date itself.

The selected Ozempic-to-Wegovy qualifying-patent dates are 2,798 days apart. May 13 to August 6, 2026 is 85 days. Neither interval predicts a generic launch, and this page no longer presents a countdown from its editorial date.

Version history

Frequently asked questions

Is there one GLP-1 patent expiration date?

No. Each drug can have several patents across several FDA products, plus separate exclusivity periods, filings, litigation, approvals, and launch milestones. A single year for a whole brand is always a simplification and can be misleading.

Is generic Ozempic available in the United States right now?

No U.S. generic Ozempic is established as available for sale. Apotex announced tentative FDA approval in April 2026. Tentative approval is not final approval and does not allow marketing.

When does the Ozempic patent expire?

There isn't one answer without specifying which product and which patent. The prior research review reported a December 5, 2031 compound-patent date; the individual patent/product association was not reverified in this update. FDA's September 14 Paragraph IV rows show last-qualifying-patent dates of February 1, 2032 or June 21, 2033 depending on the strength group. That FDA field is not a complete patent register or launch date.

When does the Wegovy patent expire?

The Paragraph IV record for standard Wegovy and Wegovy HD shows a last qualifying patent of February 17, 2041. Oral Wegovy sits under a separate application and shows February 1, 2039. Those are patent-record dates, not launch dates.

When does the Mounjaro or Zepbound patent expire?

The prior research review reported a May 13, 2036 compound-patent date; its individual patent/product association was not reverified in this update. FDA's September 14 Paragraph IV rows show last-qualifying-patent dates of December 30, 2041 for Mounjaro and July 22, 2039 for Zepbound. The previously reported August 6 litigation has not been newly docket-checked. None of these dates is a verified launch date.

Why do some articles say a semaglutide patent expired in 2026?

They may be talking about another country. Novo Nordisk reported that India's semaglutide compound patent expired March 20, 2026. Canada reached generic entry in 2026 under its own patent and data-protection history. Neither fact creates a U.S. generic.

What is a Paragraph IV certification?

It's a formal statement filed by a generic applicant saying a listed patent is invalid, unenforceable, or wouldn't be infringed by its product. It starts a legal challenge. It is not an approval and it is not a launch.

Does a Paragraph IV filing mean a generic was approved?

No. It means an application was filed with a specific type of patent challenge attached. Approval is a separate later step, and timely litigation can delay final approval.

What does tentative FDA approval mean?

It means the FDA has made a tentative approval decision, but a patent or exclusivity period still blocks final approval. The product cannot be marketed under that tentative approval.

Can a generic be approved before the last patent expires?

Sometimes. Paragraph IV challenges, court rulings, settlements, authorized generics, and the exact scope of each patent can all change the order. This is one reason the latest date in a patent table isn't a reliable launch date.

Does FDA approval mean the generic is in pharmacies?

No. The FDA states that an approved drug may not be available on or immediately after its approval date. Manufacturing, distribution, and stocking are separate events.

How much cheaper will generic GLP-1s be?

Nobody can give one percentage. Optum Rx says the first generic is often only 10–15% below brand list price, while markets with 10 or more competitors have shown 60–90% declines. These are historical August 19, 2026 advertised price observations, not current quotes: GoodRx showed $372.45 for generic Saxenda and $1,324.03 for brand Saxenda at the listed five-pen quantities, while 6 mL of generic liraglutide was $402.26–$441.53 cash on Drugs.com. Check current prices and stock separately.

Is compounded semaglutide a generic?

No. Compounded drugs are not FDA-approved finished products and are a separate category from FDA-approved generics under U.S. law. They should never be listed with generic approval status.

Why does Canada have generic Ozempic before the United States?

Different patents and different exclusivity rules. Canada's key active-ingredient patent was already listed as expired, while separate data protection ran to January 4, 2026. Health Canada approved the first generic semaglutide on April 28, 2026.

Will Trulicity have a generic?

No conventional ANDA generic. Trulicity is a biologic, so a follow-on version would use the biosimilar pathway. Its original BLA was approved September 18, 2014; the calculated 12-year anniversary passed on September 18, 2026. The prior August 19 Purple Book review did not identify a licensed dulaglutide biosimilar. This editorial update did not recheck the individual product's current exclusivity field or biosimilar-licensure status.

How often is this tracker updated?

We publish material changes when they are verified against primary sources, and date each source check and editorial update. This is not a real-time service. The Paragraph IV PDF and Sandoz product-status record were checked September 25, 2026; the Orange Book patent/product associations, litigation outcomes, Purple Book details, and retail prices have not all been newly checked for this update.

Sources

Primary U.S. regulatory sources

• FDA Orange Book: Orange Book data files, product records, patent records, exclusivity records, and FDA's Electronic Orange Book explanation
• FDA Paragraph IV: September 14, 2026 PDF, retrieved and checked September 25, 2026; SHA-256 8ec4d45eea25faf6ba3deb12114a39526817aeeba170ccad4564feaafb2e5964. The PDF's date is its source release date, not the date all other sources were checked
• FDA first generics: 2024 first-generic approvals and 2025 first-generic approvals
• FDA biologics: Purple Book and the Trulicity approval letter
• FDA compounding: Compounding and the FDA: Questions and Answers
• FDA importation: Personal Importation
• CMS: Medicare GLP-1 Bridge overview and current eligible-product details

Company, court, and market records

• Novo Nordisk A/S: Q2 2026 financial report, adjusted-sales table on printed page 8 and reconciliation on page 32; Q1 2026 SEC report for the January 1, 2027 U.S. list-price announcement; 2025 annual report for country-specific patent context
• Eli Lilly and Company: Q2 2026 Form 10-Q, filed August 5, 2026
• Sandoz litigation docket: Eli Lilly & Company v. Sandoz Inc., No. 1:26-cv-00987, filed August 6, 2026
• Apotex: U.S. tentative-approval announcement, April 10, 2026; Canadian approval announcement, May 1, 2026; Canadian launch announcement, May 14, 2026
• Hikma: generic Victoza approval and U.S. launch, December 26, 2024
• Teva: generic Saxenda approval and U.S. launch, August 28, 2025
• Amneal: exenatide approval announcement, November 21, 2024

Canada and price sources

• Health Canada: first generic semaglutide approval, April 28, 2026; second approval, May 1, 2026; first weight-loss generic, June 29, 2026; Sandoz Semaglutide DIN 02571528 approved September 16, 2026, checked September 25; Register of Innovative Drugs
• Optum Rx: Blockbuster Drug Patent Expirations in 2026 & What They Mean
• Drugs.com: Liraglutide prices, checked August 19, 2026
• GoodRx: generic Victoza and generic and brand Saxenda price pages, checked August 19, 2026

Statutes

• 35 U.S.C. § 156 — patent-term extension
• 21 U.S.C. § 355(j) — ANDA, Paragraph IV, NCE-1, and stay framework
• 42 U.S.C. § 262(k) — biosimilar pathway and reference-product exclusivity framework

About this research

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

This page was researched and written by Kaden Coziar, using the primary sources listed above. It has not been reviewed by a licensed clinician and is not medical or legal advice. It is a factual research asset about patents and regulatory status.

Found an error? We publish corrections with dates and keep old versions accessible when they are available. If a row here doesn't match the government record, tell us and we'll fix it and say what changed.

Last fully verified: August 19, 2026 · Dataset version 2.0

Still not sure which GLP-1 program is right for you? Use our free two-minute matching tool.